# Amarin share price today (Amarin Corporation plc, AMRN)

> Amarin Corporation plc's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. AMRN · Healthcare · Drug Manufacturers - General · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/amrn

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $12.05 (−26.0% in a year)
- Revenue (Jun 2026): $42.2 M (−42.0% on a year ago)
- Profit (Jun 2026): −$7.6 M
- Operating margin: −28.4% (−37.7 points on a year ago)
- ROE: −8%, FY25
- ROIC: −18.6%, against a 8.2% cost of capital: −26.8 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Amarin share price today? Amarin Corporation plc's share price was $12.05 at the close on 3 November 2026. That is 15.7% below its average price over the last 200 trading days. In the last 52 weeks it traded between $11 and $17, and at that close it sat 14% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 31 weeks running. Over the last 1 year the share price moved −29% while the S&P 500 moved +21%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 2 April 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Amarin pay? Amarin Corporation plc pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Amarin on? Amarin is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Amarin profitable? Amarin Corporation plc posted a net loss of $7.6 M in the Jun 2026 quarter. The full FY25 year was a loss of $38.8 M. That loss is 18.1% of the quarter's revenue. The same quarter a year earlier lost $14.1 M. 11 of the last 12 reported quarters were loss-making. ## How much revenue does Amarin make, and is it growing? Amarin Corporation plc reported $42.2 M of revenue in the Jun 2026 quarter, −42.0% on the same quarter a year earlier. Over 4 years it has grown −22.2% a year on average. The last full year, FY25, came in at $214 M. The last four reported quarters add to $186 M. FY25 revenue was $214 M, −6.5% on the year before. Recent pace: the last four quarters grew −9.6% on average, against −22.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −15.1%, against −16.1% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Amarin keep? Amarin Corporation plc's operating margin was −28.4% in the Jun 2026 quarter, 37.7 percentage points lower than the same quarter a year ago. Across 5 years it has been between −24.2% and 4.2%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −37.7 percentage points on the year while gross margin changed −33.7 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Amarin's profit turning into cash? Amarin Corporation plc's cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $6.7 M of operating cash against −$38.8 M of profit. After null of spending on assets, $6.7 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Amarin's cash go? Amarin Corporation plc does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $24.0 K on assets over the last 1 years. Averaged over those years that is 0.0% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $24.0 K over the last 1 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Amarin's P/E ratio, and how does it compare with its own history? Amarin Corporation plc has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Amarin Corporation plc at 1.2× its FY25 revenue of $214 M. The P/E comes back here once profit turns positive. ## Is the Amarin business getting better or worse? Amarin Corporation plc's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Amarin earn on its capital? Amarin Corporation plc earned a ROE of −8% in FY25. That is up from a low of −18% in FY22. Its return on capital used (ROIC) is 26.8 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −18.2% net margin and 0.32× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −18.2% net margin × 0.32× asset turnover × 1.46× leverage (assets divided by equity) ≈ −8.5% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −18.6% − 8.2% = −26.8 percentage points. The 8.2% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −18.6% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −7.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Amarin have too much debt? Amarin Corporation plc has total debt of $7.2 M against shareholder equity of $444 M as of Jun 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.01 in FY21 to 0.02 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Amarin shareholding pattern? We have no ownership or short-position figures for Amarin Corporation plc, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 8.7 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Amarin from balance-sheet trouble? For Amarin Corporation plc, the Z-score is −1.83. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −1.83 is inside the danger zone, so the balance sheet is a real risk. ## How does Amarin rank in its industry? 28.3 out of 100, rank 16 of 16 in Drug Manufacturers - General, with 64% of the evidence available. Amarin Corporation plc scores 28.3 out of 100 against the 16 companies it is compared with in Drug Manufacturers - General, ranking 16. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 13.2 + 3 + 11.3 + 0.8 = 28.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Amarin compared with? Amarin ranks 16 of 16 Drug Manufacturers - General companies on the 4-Factor Sector Score, with 28.3 out of 100. 1. [Eli Lilly and Company](https://www.sectoralpha.in/us/stocks/lly) LLY · turning · Sector-leading setup · 85% evidence 83.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.0/35 · Revenue 45.5% · Profit 49.8% · Operating margin change 5.4 points · 95% evidence Capital efficiency 21.4/25 · ROCE 41.7% · Operating margin 53.7% · 76% evidence Valuation 11.9/20 · P/E 37.4× · PEG 0.74 · 65% evidence Relative strength 18.4/20 · Lead over its industry 15.6% · Lead over S&P 500 23.1% · 1 year 52.5% · 100% evidence · 3 of 12 weeks ahead Exact sum: 32 + 21.4 + 11.9 + 18.4 = 83.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [AbbVie Inc.](https://www.sectoralpha.in/us/stocks/abbv) ABBV · breaking out · Most evidence points up · 85% evidence 69.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.8/35 · Revenue 10.7% · Profit 100% · Operating margin change 1.8 points · 95% evidence Capital efficiency 19.4/25 · ROCE 24.5% · Operating margin 37.3% · 76% evidence Valuation 4.4/20 · P/E 44.8× · PEG 2.67 · 65% evidence Relative strength 16.4/20 · Lead over its industry 8.4% · Lead over S&P 500 15.4% · 1 year 30.5% · 100% evidence · 10 of 12 weeks ahead Exact sum: 28.8 + 19.4 + 4.4 + 16.4 = 69 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Amgen Inc.](https://www.sectoralpha.in/us/stocks/amgn) AMGN · leader · Most evidence points up · 81% evidence 67.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.2/35 · Revenue 9.1% · Profit 32.1% · Operating margin change 2.9 points · 83% evidence Capital efficiency 15.2/25 · ROCE 18.2% · Operating margin 35.5% · 76% evidence Valuation 13.1/20 · P/E 22.4× · PEG 0.71 · 65% evidence Relative strength 15.4/20 · Lead over its industry 12.1% · Lead over S&P 500 19.3% · 1 year 44.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24.2 + 15.2 + 13.1 + 15.4 = 67.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Gilead Sciences, Inc.](https://www.sectoralpha.in/us/stocks/gild) GILD · leader · Evidence leans up · 75% evidence 63.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue 6.5% · Profit -147.6% · Operating margin change -1.8 points · 95% evidence Capital efficiency 19.4/25 · ROCE 30.3% · Operating margin 43.4% · 76% evidence Valuation 11.5/20 · P/E -47.8× · PEG n/a · 15% evidence Relative strength 17.6/20 · Lead over its industry 9.1% · Lead over S&P 500 16% · 1 year 40.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 14.6 + 19.4 + 11.5 + 17.6 = 63.1 · What this means: Relative strength against the index is 16%, and revenue and profit growth are weak. 5. [GSK plc](https://www.sectoralpha.in/us/stocks/gsk) GSK · basing · Evidence leans up · 81% evidence 60.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 5% · Profit 32.1% · Operating margin change 0.9 points · 83% evidence Capital efficiency 19.8/25 · ROCE 25.1% · Operating margin 30.9% · 76% evidence Valuation 14.5/20 · P/E 16.4× · PEG 0.39 · 65% evidence Relative strength 0.9/20 · Lead over its industry -15.7% · Lead over S&P 500 -10.3% · 1 year 4.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25 + 19.8 + 14.5 + 0.9 = 60.2 · What this means: Earnings are strong; relative strength in its sector is -15.7% and the one-year return is 4.4%. 6. [Bristol-Myers Squibb Company](https://www.sectoralpha.in/us/stocks/bmy) BMY · quiet · Evidence leans up · 81% evidence 59.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.6/35 · Revenue 3.1% · Profit 83.8% · Operating margin change 0.7 points · 83% evidence Capital efficiency 18.1/25 · ROCE 22.7% · Operating margin 34.4% · 76% evidence Valuation 14.3/20 · P/E 12.7× · PEG 0.5 · 65% evidence Relative strength 4.0/20 · Lead over its industry -5.7% · Lead over S&P 500 0.4% · 1 year 32.2% · 100% evidence · 5 of 12 weeks ahead Exact sum: 22.6 + 18.1 + 14.3 + 4 = 59 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [AstraZeneca PLC](https://www.sectoralpha.in/us/stocks/azn) AZN · turning · Evidence leans up · 85% evidence 50.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.2/35 · Revenue 7.3% · Profit 17.4% · Operating margin change 3 points · 95% evidence Capital efficiency 14.2/25 · ROCE 17.6% · Operating margin 27.1% · 76% evidence Valuation 10.0/20 · P/E 22.9× · PEG 1.33 · 65% evidence Relative strength 7.3/20 · Lead over its industry -9.4% · Lead over S&P 500 -3.6% · 1 year 10.7% · 100% evidence · 2 of 12 weeks ahead Exact sum: 19.2 + 14.2 + 10 + 7.3 = 50.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Sanofi](https://www.sectoralpha.in/us/stocks/sny) SNY · turning · Evidence leans down · 66% evidence 49.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.6/35 · Revenue n/a · Profit n/a · Operating margin change 5.1 points · 39% evidence Capital efficiency 9.2/25 · ROCE 10.7% · Operating margin 21% · 76% evidence Valuation 14.5/20 · P/E 22.8× · PEG 0.33 · 65% evidence Relative strength 5.4/20 · Lead over its industry -10.8% · Lead over S&P 500 -5% · 1 year -8.7% · 100% evidence · 1 of 12 weeks ahead Exact sum: 20.6 + 9.2 + 14.5 + 5.4 = 49.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Organon & Co.](https://www.sectoralpha.in/us/stocks/ogn) OGN · turning · Evidence leans down · 81% evidence 49.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 9.3/35 · Revenue -2.5% · Profit -70.1% · Operating margin change -0.9 points · 83% evidence Capital efficiency 10.8/25 · ROCE 11.5% · Operating margin 20.7% · 76% evidence Valuation 15.5/20 · P/E 17× · PEG 0.17 · 65% evidence Relative strength 13.9/20 · Lead over its industry 15.2% · Lead over S&P 500 23% · 1 year 104.3% · 100% evidence · 0 of 12 weeks ahead Exact sum: 9.3 + 10.8 + 15.5 + 13.9 = 49.5 · What this means: Relative strength against the index is 23%, and revenue and profit growth are weak. 10. [Biogen Inc.](https://www.sectoralpha.in/us/stocks/biib) BIIB · breaking out · Evidence leans down · 81% evidence 46.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 7.9/35 · Revenue 0.3% · Profit -45.4% · Operating margin change -9.2 points · 83% evidence Capital efficiency 7.9/25 · ROCE 8.9% · Operating margin 25.1% · 76% evidence Valuation 13.3/20 · P/E 38.2× · PEG 0.38 · 65% evidence Relative strength 17.5/20 · Lead over its industry 12.8% · Lead over S&P 500 20.1% · 1 year 60.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 7.9 + 7.9 + 13.3 + 17.5 = 46.6 · What this means: Relative strength against the index is 20.1%, and revenue and profit growth are weak. 11. [Johnson & Johnson](https://www.sectoralpha.in/us/stocks/jnj) JNJ · turning · Evidence leans down · 75% evidence 46.3 out of 100 Growth Capital Valuation Relative
12. [Novartis AG](https://www.sectoralpha.in/us/stocks/nvs) NVS · turning · Evidence leans down · 85% evidence 46.0 out of 100 Growth Capital Valuation Relative
13. [Pfizer Inc.](https://www.sectoralpha.in/us/stocks/pfe) PFE · leader · Evidence leans down · 71% evidence 44.5 out of 100 Growth Capital Valuation Relative
14. [Merck & Co., Inc.](https://www.sectoralpha.in/us/stocks/mrk) MRK · leader · Evidence leans down · 85% evidence 41.9 out of 100 Growth Capital Valuation Relative
15. [Grifols, S.A.](https://www.sectoralpha.in/us/stocks/grfs) GRFS · turning · Evidence leans down · 71% evidence 41.3 out of 100 Growth Capital Valuation Relative
16. Amarin Corporation plc this page AMRN · basing · Most evidence points down · 64% evidence 28.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.2/35 · Revenue -15.1% · Profit n/a · Operating margin change -37.7 points · 62% evidence Capital efficiency 3.0/25 · ROCE -5.2% · Operating margin -28.4% · 76% evidence Valuation 11.3/20 · P/E -8.4× · PEG n/a · 15% evidence Relative strength 0.8/20 · Lead over its industry -25.3% · Lead over S&P 500 -20.5% · 1 year -23.3% · 100% evidence · 0 of 12 weeks ahead Exact sum: 13.2 + 3 + 11.3 + 0.8 = 28.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Drug Manufacturers - General](https://www.sectoralpha.in/us/sectors/drug-manufacturers-general), all 16 compared on one page. ## Which companies are close to Amarin in size? Amarin is the 17th largest of 17 Drug Manufacturers - General companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Bristol-Myers Squibb Company, Sanofi, GSK plc, Biogen Inc., Grifols, S.A. and Organon & Co. It is the smallest. ### Drug Manufacturers - General companies close in size

1. [Bristol-Myers Squibb Company](https://www.sectoralpha.in/us/stocks/bmy) $126.1 billion
2. [Sanofi](https://www.sectoralpha.in/us/stocks/sny) $108.1 billion
3. [GSK plc](https://www.sectoralpha.in/us/stocks/gsk) $97.4 billion
4. [Biogen Inc.](https://www.sectoralpha.in/us/stocks/biib) $36.8 billion
5. [Grifols, S.A.](https://www.sectoralpha.in/us/stocks/grfs) $7.6 billion
6. [Organon & Co.](https://www.sectoralpha.in/us/stocks/ogn) $3.6 billion
7. Amarin Corporation plc $254 million

[All 17 Drug Manufacturers - General companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-general#all-companies)

### Companies close in size in other industries

1. [National Bankshares, Inc.](https://www.sectoralpha.in/us/stocks/nksh) $256 million · Banks - Regional
2. [TechTarget, Inc.](https://www.sectoralpha.in/us/stocks/ttgt) $255 million · Information Technology Services
3. Amarin Corporation plc $255 million
4. [Lotus Technology Inc.](https://www.sectoralpha.in/us/stocks/lot) $254 million · Auto Manufacturers
5. [BRT Apartments Corp.](https://www.sectoralpha.in/us/stocks/brt) $253 million · REIT - Residential

## What else do people ask about Amarin? ### What were Amarin's latest quarterly results? Amarin Corporation plc reported revenue of $42.2 M and a net loss of $7.6 M for the Jun 2026 quarter. Earnings per share were −$0.40. The operating margin was −28.4%, 37.7 percentage points lower than a year earlier (as of 3 November 2026). ### What is Amarin's market cap? Amarin Corporation plc's market capitalisation is $254 M at a stock price of $12.05. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Amarin performing? Amarin Corporation plc's latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 31 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Amarin's stock price go up? This page does not forecast Amarin Corporation plc's stock price. What it shows instead: the stock price is $12.05. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Amarin in its business cycle? Amarin Corporation plc's FY25 operating margin was −6.5%, against a 5-year range of −24.2% to 4.2%: the middle of its own range, neither a peak nor a low. The latest quarter was −28.4%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Amarin story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Amarin a stock worth studying right now? What the numbers show: Amarin Corporation plc's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.